These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
    Author: Markman M, Webster K, Kulp B, Peterson G.
    Journal: Cancer Invest; 2005; 23(1):33-5. PubMed ID: 15779866.
    Abstract:
    BACKGROUND: The optimal duration of therapy for women with platinum-resistant ovarian cancer who respond to second-line treatment programs remains undefined. CASE REPORT: A patient with well-documented platinum-resistant ovarian cancer who responded to single-agent paclitaxel (175 mg/m2 over 3 hours q 28-35 days) was continued on this program for a total of 15 cycles delivered over a period of 16 months. The patient has subsequently remained without evidence of disease recurrence >7 years following discontinuation of this treatment regimen. CONCLUSION: The prolonged administration of paclitaxel, a highly cycle-specific cytotoxic agent, is a rational management option in patients with platinum-resistant ovarian cancer who exhibit evidence of a response to therapy and who do not experience excessive treatment-associated toxicity (e.g., grade 2-3 peripheral neuropathy).
    [Abstract] [Full Text] [Related] [New Search]